Acute Lymphoblastic Leukemia – Landscape & Forecast – Disease Landscape & Forecast
The acute lymphoblastic leukemia (ALL) therapy market is growing steadily, fueled by innovations in the treatment paradigm. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Blincyto-based therapies, is impacting the disease’s treatment algorithm. Although multiagent chemotherapy remains the cornerstone of treatment, recently approved therapies (Amgen’s Blincyto and Pfizer’s Besponsa) have expanded the number of options available. CAR T-cell therapies (Novartis’s Kymriah and Kite Pharma’s Tecartus) have also expanded options in the relapse and refractory setting, offering patients additional support. The emerging therapy pipeline continues to grow with therapies such as AbbVie / Roche’s Venclexta / Venclyxto and Bristol Myers Squibb’s CAR T-cell therapy Breyanzi showing promising development. Nevertheless, clinical and commercial potential remains for ALL therapies with improved efficacy, a novel mechanism of action, and/or the ability to treat underserved patient segments, such as T-cell ALL.
Questions answered
- What is the size of the drug-treatable ALL population, and how do the drug-treatment rates vary by geography, line of therapy, and by age?
- How will the use of chemotherapy change over the forecast period, and what impact will the entry of generics have on the ALL market?
- What are thought leaders’ opinions of anti-CD19 CAR T-cell therapies that are approved or in Phase II/III development, such as Kymriah, Tecartus, and Breyanzi?
- What are the drivers of, and constraints on, the ALL market?
- How will the entry of new agents shape this market?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Acute Lymphoblastic Leukemia - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market outlook
- Key findings
- Market share of drug classes for ALL: 2021
- Market share of drug classes for ALL: 2031
- Drug-treatable population share and major-market sales share in ALL: 2021
- Drug-treatable population share and major-market sales share in ALL: 2031
- Major-market sales of key agents in ALL: 2021-2031
- Population positioning of current therapies in ALL
- Population positioning of emerging therapies in ALL
- ALL SWOT analysis
- Market drivers and constraints
- Segment-specific trends
- Key findings
- Forecast
- Etiology and pathophysiology
- Epidemiology
- Current treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for ALL
- Current treatments used for ALL
- Market events impacting the use of key current therapies for ALL
- Tyrosine kinase inhibitors
- Chemotherapy and novel formulations
- Monoclonal antibodies
- Bispecific antibodies
- Antibody-drug conjugates
- CAR T-cell therapies
- Medical practice
- Key findings
- Unmet need overview
- Drug pipeline
- Emerging therapies
- Access & reimbursement overview
- Methodology
- Appendix
Elliott Puttock, M.Res., Ph.D., is an analyst on the Oncology team at Clarivate. He has experience working in the pharmaceutical sector developing novel therapeutics for ongoing oncology projects. While earning his Ph.D., he specialized in metastatic ovarian cancer and focused on targeting the extracellular matrix to develop new treatments for patients. He obtained his doctorate from Barts Cancer Institute in London.
Yueyao (Alex) Li, M.D., Ph.D., M.S.P.H., is an associate epidemiologist at Clarivate. Previously, she was a postdoctoral researcher at Brown University, where she worked on projects relating to skin cancer and chronic skin conditions. Dr. Li holds a medical degree specializing in general surgery from China Medical University. She also holds a Ph.D. in epidemiology from Indiana University and a master’s degree in public health from the University of South Carolina.